Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Mar 02, 2026
Why Did AeroVironment, Inc. (AVAV) Stock Move Up +16.83% Today?

Why Did AeroVironment, Inc. (AVAV) Stock Move Up +16.83% Today?

Key Takeaways

  • AVAV surged +16.83% in Monday's session, trading at $294.70 compared to Friday's closing price of $252.25 — a gain of $42.45 per share
  • The primary catalyst was a powerful confluence of geopolitical demand and corporate developments: the escalating U.S.-Iran military conflict dramatically amplified investor focus on AeroVironment's loitering munitions portfolio
  • A major secondary driver was the real-world operational deployment of AeroVironment's LOCUST counter-drone laser system at a U.S. airport, validating the technology at scale
  • JPMorgan Chase analyst Seth Seifman initiated coverage of AVAV with an Overweight rating and a $320 price target, adding Wall Street conviction behind the rally
  • The broader defense sector moved sharply higher in sympathy, with LMT, PLTR, and peer drone-focused names all posting significant gains
  • Investors are now closely watching the scheduled Q3 FY2026 earnings release for AVAV on March 3, 2026, with analysts projecting $0.72 EPS on revenue of approximately $487.94 million

Opening Summary

AeroVironment, Inc. (AVAV) is a U.S. defense technology company specializing in unmanned aerial systems, loitering munitions — including the battle-proven Switchblade family of kamikaze drones — and counter-drone technologies. Shares surged +16.83% in Monday's trading session, March 2, 2026, rising from a prior close of $252.25 to $294.70, with an intraday high of $298.00. The rally was driven by a rare convergence of geopolitical escalation involving the United States and Iran, the confirmed operational deployment of AeroVironment's LOCUST counter-drone laser system at a domestic airport, and fresh analyst coverage from JPMorgan Chase — all of which arrived simultaneously, igniting broad-based demand for shares of a company at the center of modern drone warfare.

Iran Conflict Puts Drone Stocks in Focus

The sharpest and most immediate catalyst behind the AVAV price rally was the escalating U.S.-Iran military confrontation, which placed loitering munitions — often called kamikaze drones — at the forefront of market and geopolitical attention. AeroVironment's Switchblade 300 and 600 systems are among the most widely deployed loitering munitions in U.S. allied arsenals, making AVAV the most direct equity expression of the drone warfare theme in public markets. Wall Street's rapid rerating on Monday reflected the belief that sustained conflict at this level could accelerate procurement timelines and unlock additional contract vehicles for AeroVironment's core product lines well beyond existing guidance.

The broader defense sector moved sharply in the same direction, with LMT gaining +3.46% and PLTR advancing +4.60%, confirming that the geopolitical risk premium was being priced across the sector. However, AVAV's +16.83% move was far more pronounced than sector peers, reflecting its uniquely concentrated exposure to precisely the class of autonomous weapon systems driving the current conflict narrative.

LOCUST Deployment Validates Counter-Drone Technology

A critical company-specific catalyst compounding Monday's rally was the confirmed deployment of AeroVironment's LOCUST system — a counter-drone directed-energy laser — at a U.S. airport. This operational milestone transformed LOCUST from a development-stage technology into a revenue-generating deployed asset, significantly de-risking what had previously been viewed as a speculative product line. The deployment announcement, which arrived in the week prior and continued to reverberate in Monday's session, provided direct evidence that AeroVironment's counter-UAS portfolio is progressing from contracts to real-world operations.

The event also drew the attention of JPMorgan Chase analyst Seth Seifman, who used the LOCUST deployment as a key rationale when initiating coverage of AVAV with an Overweight (Buy) rating and a $320 price target. At the time of the initiation, that target represented approximately 31% upside from then-prevailing prices — a gap that the stock has since moved aggressively to close.

Upcoming Q3 Earnings Add to Anticipatory Buying

Adding fuel to the rally was the imminent Q3 FY2026 earnings report, scheduled for release before the market open on March 3, 2026. With analyst consensus projecting EPS of $0.72 and revenue of approximately $487.94 million — the latter implying continued robust growth aided by the BlueHalo acquisition — investors appeared to be positioning ahead of a potential positive earnings catalyst on top of the geopolitical tailwind. The forward expectations represented a meaningful improvement over Q2 FY2026's EPS miss, and the bullish sentiment surrounding drone demand provided a constructive backdrop for earnings anticipation buying.

AeroVironment entered the session with a record backlog, all-time high bookings of nearly $1.4 billion, and a total contract award ceiling of $3.5 billion — fundamental underpinnings that give long-term confidence even amid short-term margin pressures. Full-year FY2026 guidance stood at approximately $1.98 billion in revenue, and analysts covering the stock had a consensus price target near $361–$372 heading into the week, implying significant upside from pre-rally levels.

Market Context and Trading Activity

Volume in AVAV on Monday reached approximately 826,971 shares traded by mid-session, compared to an average daily volume of 1,408,805 — but given the session is still open, total daily volume is expected to finish well above average. The stock opened at $284.24, immediately gapping up from Friday's close of $252.25, and reached a session high of $298.00, remaining elevated throughout the day as buyers sustained the momentum. The move brought AVAV back above its 50-day moving average of $283.70 and also above its 200-day moving average of $272.27 — a meaningful technical recapture that could draw additional momentum-driven interest.

The broader market backdrop was mixed, with Wall Street futures under pressure from Middle East conflict concerns, yet paradoxically serving as a tailwind specifically for defense names like AVAV. The divergence between the broader indices and defense stocks on Monday underscored how sector-specific the catalyst was: geopolitical escalation simultaneously weighed on risk assets while boosting companies whose products are central to the conflict.

Trending AI Robots

For active traders tracking fast-moving defense and technology names like AVAV, Tickeron's platform offers hundreds of AI-powered trading bots covering thousands of tickers across multiple strategies and asset classes. However, only the highest-performing bots under current market conditions earn a spot in the curated Trending AI Robots section. These bots differ by trading strategy — including momentum, swing, and mean reversion — as well as by timeframe, risk profile, performance metrics, and the symbols they cover. The section is updated regularly to reflect live market dynamics, making it a practical resource for identifying which algorithmic approaches are generating the strongest edge right now. Traders looking to systematically capitalize on volatility events like today's AVAV surge are encouraged to explore what Tickeron's Trending AI Robots have to offer.

What Comes Next for AVAV

The most immediate event on the calendar is the Q3 FY2026 earnings release, scheduled before the market open on March 3, 2026, with analyst consensus at $0.72 EPS and $487.94 million in revenue. The report will be closely scrutinized for gross margin recovery progress — a key concern following the Q2 EPS miss attributed to BlueHalo integration costs, ERP system disruptions, and government shutdown-related delays. Management commentary on the Switchblade IQ program, international orders linked to the Iran conflict, and the pace of CFO transition following Kevin McDonnell's planned July 2026 retirement will all be important signals.

Analyst sentiment heading into the report was overwhelmingly bullish, with 17 analysts projecting approximately 42% upside and a consensus Overweight rating. Key risks include continued margin compression from acquisition accounting, potential delays in U.S. government task order issuance, and any de-escalation of the Iran conflict that could reduce the perceived urgency of drone procurement spending. The stock now trades above both its 50-day and 200-day moving averages following Monday's surge, setting up the earnings print as the next critical decision point for investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: AVAV

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


AVAV's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for AVAV turned positive on July 22, 2026. Looking at past instances where AVAV's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on AVAV as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

AVAV moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AVAV crossed bullishly above the 50-day moving average on August 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AVAV advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 225 cases where AVAV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AVAV moved out of overbought territory on August 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVAV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AVAV broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AVAV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVAV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock worse than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.217) is normal, around the industry mean (10.124). P/E Ratio (149.026) is within average values for comparable stocks, (90.717). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.189). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (4.787) is also within normal values, averaging (26.089).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 43.1B. The market cap for tickers in the group ranges from 4.49 to 1.85T. SPCX holds the highest valuation in this group at 1.85T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 3%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 8%. DFSC experienced the highest price growth at 138%, while EVTL experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 44% and the average quarterly volume growth was 71%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 65
Price Growth Rating: 51
SMR Rating: 78
Profit Risk Rating: 71
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
AVAV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of unmanned aircraft and charging systems

Industry AerospaceDefense

Profile
Details
Industry
Aerospace And Defense
Address
241 18th Street South
Phone
+1 703 418-2828
Employees
3731
Web
https://www.avinc.com
Interact to see
Advertisement
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Cincinnati Financial (CINF) reports Q4 2025 earnings on February 9, 2026, after market close, with consensus EPS of $2.86–$2.89 and revenue around $2.91 billion. Allstate (ALL) recently reported Q4 2025 EPS of $14.31, well above the $8.72 estimate, with revenue of $17.3 billion on February 4, 2026.
Coca-Cola (KO) reports Q4 2025 earnings on February 10, 2026, with consensus EPS of $0.56 and revenue of $12.05 billion. PepsiCo (PEP) beat Q4 2025 estimates on February 3, reporting adjusted EPS of $2.26 (vs. $2.24 expected) and revenue of $29.34 billion.
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside. Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.